FDA Issues Warning Letters to 7 Companies Marketing Unapproved GLP-1 Products
The FDA sent warning letters to seven companies for selling products marketed as GLP-1 receptor agonists that were not approved, cleared, or authorized by the FDA.
Key Takeaways
- 7 companies warned for selling unapproved GLP-1 products
- Includes dietary supplements falsely claiming GLP-1 activity
- Different from March 2026 warnings which targeted marketing claims
- Legitimate GLP-1 medications always require a prescription
What Happened
On April 7, 2026, the FDA issued warning letters to seven companies for marketing products as GLP-1 receptor agonists without FDA approval. Unlike the March 2026 warning letters (which targeted misleading marketing by telehealth companies), these letters targeted companies selling products that the FDA determined were unapproved new drugs.
Key Differences
This enforcement action targets a different category of violation. While the March letters addressed misleading marketing claims by legitimate telehealth companies, these April letters target companies selling products that lack any FDA authorization. This includes dietary supplements falsely marketed as containing GLP-1 activity and unregistered entities selling injectable products.
What Consumers Should Know
Be cautious of products sold outside of the traditional prescription telehealth or pharmacy model. Legitimate GLP-1 medications require a prescription and come from either an FDA-approved manufacturer or a registered compounding pharmacy.
Source: View original on FDA.gov
Disclaimer: This article summarizes publicly available FDA data for informational purposes only. It is not medical or legal advice. Always consult your healthcare provider and verify with official FDA sources before making decisions about your treatment.
Related Safety Guides
GLP-1 Safety Alerts
Get notified when the FDA issues warning letters, recalls, or regulatory updates affecting GLP-1 medications and compounding pharmacies.
Free. No spam. Unsubscribe anytime.